Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8+ T cells
TP5 strengthens oncolytic virotherapy by orchestrating macrophages and CD8<sup>+</sup> T cells to attack tumors. Its dual use, as a combination drug or engineered into viruses, offers a practical strategy to improve clinical outcomes. This approach provides a low-cost method to amplify oncolytic virus efficacy and inspires designs where single therapies mimic combination effects, advancing accessible cancer immunotherapy.
Authors
- Ke Zhou (ORCID: https://orcid.org/0000-0002-2161-8796)
- Fangkun Zhao (ORCID: https://orcid.org/0000-0002-9865-4584)
- Kua Liu
- Huawei Cui
- Jiannan Qiu (ORCID: https://orcid.org/0000-0002-6736-7224)
- Cen Jiang (ORCID: https://orcid.org/0000-0003-2690-6890)
- Lingkai Kong (ORCID: https://orcid.org/0009-0002-0972-1202)
- Xiaosong Gu
- Peng Wang
- Qilei Xin
- Junhua Wu
- Yan Liu
- Junnan Wu
- Wencui Liu
Institutions
- Fujian Medical University (CN)
- Shandong University (CN)
- Nanjing Drum Tower Hospital (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
- Jinan Stomatological Hospital (CN)
- Nanjing University (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1038/s43856-026-01509-6
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Shandong Province
- Nanjing University